7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline
Yahoo Finance · 3 weeks ago
Open | 138.25 |
High | 139.72 |
Low | 135.85 |
Mkt Cap | 14B |
P/E (TTM) | 37.79 |
Div & Yield | N/A & N/A |
Prev. Close | 138.23 |
52 Wk. Low | 93.28 |
52 Wk. High | 148.37 |
Related stocks
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. The company is headquartered in San Diego, California, and led by CEO Kevin Gorman. Wikipedia
(USD) | Q1 2024 | Y/Y |
---|---|---|
Revenue | 515.3M | 22.60% ▲ |
Net Income | 43.4M | - |
Diluted EPS | 0.42 | - |
Quarter | EPS Estimate | EPS Actual |
---|---|---|
Q2 2024 | $1.03 | - |
Q1 2024 | $1.01 | $0.42 |
Q4 2023 | $1.14 | $1.44 |
S&P 500^GSPC | 5,567.19+30.17 (+0.54%) |
Dow 30^DJI | 39,375.87+67.87 (+0.17%) |
Nasdaq^IXIC | 18,352.76+164.46 (+0.90%) |
539.91+5.87% | |
171.90+4.88% | |
27.23+5.34% |